NVRO Fundamental Analysis - NEVRO CORP

Name: NEVRO CORP (NVRO) Stock
Brand: NEVRO CORP
Rating: 5 (3 reviews)

Fundamental Rating

Taking everything into account, NVRO scores 2 out of 10 in our fundamental rating. NVRO was compared to 189 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of NVRO have multiple concerns. NVRO is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year NVRO has reported negative net income.

NVRO had a negative operating cash flow in the past year.

NVRO had negative earnings in 4 of the past 5 years.

In multiple years NVRO reported negative operating cash flow during the last 5 years.

1.2 Ratios

NVRO has a Return On Assets (-20.48%) which is in line with its industry peers.

With a Return On Equity value of -49.11%, NVRO perfoms like the industry average, outperforming 48.17% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-20.48%
ROE	-49.11%
ROIC	N/A

ROA(3y)-11.5%

ROA(5y)-13.58%

ROE(3y)-26.55%

ROE(5y)-28.86%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

With a decent Gross Margin value of 65.98%, NVRO is doing good in the industry, outperforming 68.06% of the companies in the same industry.

NVRO's Gross Margin has been stable in the last couple of years.

NVRO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	65.98%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-1.17%

GM growth 5Y-0.71%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

NVRO does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, NVRO has more shares outstanding

NVRO has more shares outstanding than it did 5 years ago.

The debt/assets ratio for NVRO is higher compared to a year ago.

2.2 Solvency

NVRO has an Altman-Z score of -0.62. This is a bad value and indicates that NVRO is not financially healthy and even has some risk of bankruptcy.

With a Altman-Z score value of -0.62, NVRO perfoms like the industry average, outperforming 42.93% of the companies in the same industry.

A Debt/Equity ratio of 0.98 indicates that NVRO is somewhat dependend on debt financing.

Looking at the Debt to Equity ratio, with a value of 0.98, NVRO is doing worse than 73.30% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	0.98
Debt/FCF	N/A
Altman-Z	-0.62

ROIC/WACCN/A

WACC8.29%

2.3 Liquidity

NVRO has a Current Ratio of 4.62. This indicates that NVRO is financially healthy and has no problem in meeting its short term obligations.

NVRO's Current ratio of 4.62 is fine compared to the rest of the industry. NVRO outperforms 73.82% of its industry peers.

A Quick Ratio of 3.62 indicates that NVRO has no problem at all paying its short term obligations.

The Quick ratio of NVRO (3.62) is better than 70.68% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	4.62
Quick Ratio	3.62

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 25.29% over the past year.

Looking at the last year, NVRO shows a decrease in Revenue. The Revenue has decreased by -3.92% in the last year.

Measured over the past years, NVRO shows a small growth in Revenue. The Revenue has been growing by 0.92% on average per year.

EPS 1Y (TTM)25.29%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-60%

Revenue 1Y (TTM)-3.92%

Revenue growth 3Y1.83%

Revenue growth 5Y0.92%

Sales Q2Q%-9.15%

3.2 Future

NVRO is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.68% yearly.

Based on estimates for the next years, NVRO will show a small growth in Revenue. The Revenue will grow by 4.43% on average per year.

EPS Next Y-29.92%

EPS Next 2Y-6.37%

EPS Next 3Y-1.23%

EPS Next 5Y7.68%

Revenue Next Year0.32%

Revenue Next 2Y2.33%

Revenue Next 3Y3.23%

Revenue Next 5Y4.43%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NVRO. In the last year negative earnings were reported.

Also next year NVRO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-6.37%

EPS Next 3Y-1.23%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for NVRO!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

NEVRO CORP

NYSE:NVRO (4/2/2025, 8:04:00 PM)

After market: 5.8401 0 (0%)

5.84

0 (0%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Equipment & Supplies

Earnings (Last)03-04 2025-03-04/amc

Earnings (Next)05-05 2025-05-05/amc

Inst Owners99.47%

Inst Owner Change0%

Ins Owners2.02%

Ins Owner Change0%

Market Cap221.22M

Revenue(TTM)408.52M

Net Income(TTM)-113.44M

Analysts53.68

Price Target8.87 (51.88%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)49.9%

Min EPS beat(2)49.33%

Max EPS beat(2)50.46%

EPS beat(4)4

Avg EPS beat(4)42.48%

Min EPS beat(4)24.11%

Max EPS beat(4)50.46%

EPS beat(8)8

Avg EPS beat(8)30.85%

EPS beat(12)11

Avg EPS beat(12)217.02%

EPS beat(16)15

Avg EPS beat(16)164.13%

Revenue beat(2)2

Avg Revenue beat(2)1.5%

Min Revenue beat(2)0.92%

Max Revenue beat(2)2.09%

Revenue beat(4)3

Avg Revenue beat(4)0.05%

Min Revenue beat(4)-4.87%

Max Revenue beat(4)2.09%

Revenue beat(8)5

Avg Revenue beat(8)0.76%

Revenue beat(12)5

Avg Revenue beat(12)0.11%

Revenue beat(16)7

Avg Revenue beat(16)0.05%

PT rev (1m)0%

PT rev (3m)10.28%

EPS NQ rev (1m)0%

EPS NQ rev (3m)6.89%

EPS NY rev (1m)0.24%

EPS NY rev (3m)1.14%

Revenue NQ rev (1m)-1.34%

Revenue NQ rev (3m)-1.97%

Revenue NY rev (1m)-0.01%

Revenue NY rev (3m)0.21%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	0.54
P/FCF	N/A
P/OCF	N/A
P/B	0.96
P/tB	1.07
EV/EBITDA	N/A

EPS(TTM)-1.92

EYN/A

EPS(NY)-2.49

Fwd EYN/A

FCF(TTM)-0.77

FCFYN/A

OCF(TTM)-0.51

OCFYN/A

SpS10.78

BVpS6.1

TBVpS5.45

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-20.48%
ROE	-49.11%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	65.98%
FCFM	N/A

ROA(3y)-11.5%

ROA(5y)-13.58%

ROE(3y)-26.55%

ROE(5y)-28.86%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-1.17%

GM growth 5Y-0.71%

F-Score2

Asset Turnover0.74

Health

		Industry Rank	Sector Rank
Debt/Equity	0.98
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	89.79%
Cap/Sales	2.4%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	4.62
Quick Ratio	3.62
Altman-Z	-0.62

F-Score2

WACC8.29%

ROIC/WACCN/A

Cap/Depr(3y)111.23%

Cap/Depr(5y)142.49%

Cap/Sales(3y)2.09%

Cap/Sales(5y)2.23%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)25.29%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-60%

EPS Next Y-29.92%

EPS Next 2Y-6.37%

EPS Next 3Y-1.23%

EPS Next 5Y7.68%

Revenue 1Y (TTM)-3.92%

Revenue growth 3Y1.83%

Revenue growth 5Y0.92%

Sales Q2Q%-9.15%

Revenue Next Year0.32%

Revenue Next 2Y2.33%

Revenue Next 3Y3.23%

Revenue Next 5Y4.43%

EBIT growth 1Y11.35%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year86.02%

EBIT Next 3Y28.25%

EBIT Next 5Y19.53%

FCF growth 1Y56.65%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y66.96%

OCF growth 3YN/A

OCF growth 5YN/A

NEVRO CORP / NVRO FAQ

What is the fundamental rating for NVRO stock?

ChartMill assigns a fundamental rating of 2 / 10 to NVRO.

Can you provide the valuation status for NEVRO CORP?

ChartMill assigns a valuation rating of 0 / 10 to NEVRO CORP (NVRO). This can be considered as Overvalued.

How profitable is NEVRO CORP (NVRO) stock?

NEVRO CORP (NVRO) has a profitability rating of 2 / 10.

What is the earnings growth outlook for NEVRO CORP?

The Earnings per Share (EPS) of NEVRO CORP (NVRO) is expected to decline by -29.92% in the next year.

NEVRO CORP (NVRO) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

NEVRO CORP / NVRO FAQ

What is the fundamental rating for NVRO stock?

Can you provide the valuation status for NEVRO CORP?

How profitable is NEVRO CORP (NVRO) stock?

What is the earnings growth outlook for NEVRO CORP?